Denosumab-A powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts

Research output: Article

4 Citations (Scopus)

Abstract

Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.

Original languageEnglish
Pages (from-to)743-747
Number of pages5
JournalPathology and Oncology Research
Volume18
Issue number4
DOIs
Publication statusPublished - okt. 2012

Fingerprint

Osteoclasts
Neoplasm Metastasis
Bone and Bones
Cathepsin K
Selective Estrogen Receptor Modulators
src-Family Kinases
Bone Diseases
Diphosphonates
Quality of Life
Costs and Cost Analysis
Denosumab
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{9209766114324b18bef1ab6031e2a57d,
title = "Denosumab-A powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts",
abstract = "Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.",
keywords = "Denosumab, Metastasis, Osteoclasts, RANKL-inhibitor",
author = "L. K{\'o}pper",
year = "2012",
month = "10",
doi = "10.1007/s12253-012-9538-4",
language = "English",
volume = "18",
pages = "743--747",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Denosumab-A powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts

AU - Kópper, L.

PY - 2012/10

Y1 - 2012/10

N2 - Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.

AB - Denosumab is a perfect example on the targeted anticancer therapy. The inhibition of RANKL activity suppressed the osteoclasts' resorptive function and so prevented skeletal related events. This effect is useful not only against bone metastases, but also in the treatment of other diseases caused by bone loss. In different solid tumors with bone metastasis the quality of life also improved, although the overall survival usually showed no change. On the market the main competitors for denosumab are still the bisphosphonates (questions of costs and reimbursement are not discussed) and some potential new agents e.g. Src kinases (as dasatinib, saracatinib, bosutinib), cathepsin K inhibitors, (e.g. odanacatib), and new selective estrogen receptor modulators (e.g. bazedoxifene, lasofoxifene). Nevertheless, today denosumab is one of the most powerful agents in bone-saving area.

KW - Denosumab

KW - Metastasis

KW - Osteoclasts

KW - RANKL-inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84868471050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868471050&partnerID=8YFLogxK

U2 - 10.1007/s12253-012-9538-4

DO - 10.1007/s12253-012-9538-4

M3 - Article

C2 - 22588706

AN - SCOPUS:84868471050

VL - 18

SP - 743

EP - 747

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 4

ER -